Institutional Ownership
Aligos Therapeutics Inc
CUSIP 01626L105StockALGSQ1 2026
13D / 13G Filings
41
Schedule 13D/13G on record
Beneficial Filers
18
Distinct reporting persons
Largest Stake
15.3%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
41 filings · latest Nov 14, 2024
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 14, 2024 | Alyeska Investment Group, L.P. | 13G/A | 4.8% | 146.5K | SEC |
| 2 | Feb 14, 2024 | Tang Capital Partners LP | 13G/A | 3.0% | 2.19M | SEC |
| 3 | Feb 14, 2024 | Armistice Capital, LLC | 13G | 10.0% | 7.21M | SEC |
| 4 | Feb 14, 2024 | Alyeska Investment Group, L.P. | 13G | 10.0% | 7.18M | SEC |
| 5 | Feb 14, 2024 | Baker Bros. Advisors LP | 13G/A | 5.0% | 3.66M | SEC |
| 6 | Feb 14, 2024 | Ecor1 Capital, LLC | 13G/A | 10.0% | 7.26M | SEC |
| 7 | Feb 14, 2024 | Hhlr Advisors, Ltd. | 13G/A | 8.2% | 5.97M | SEC |
| 8 | Feb 8, 2024 | Versant Venture Capital Vi, L.P. | 13D/A | 1.9% | 1.46M | SEC |
| 9 | Nov 7, 2023 | Roche Finance Ltd | 13G/A | 15.3% | 11.03M | SEC |
| 10 | Nov 6, 2023 | Blatt Lawrence | 13D | 5.3% | 3.89M | SEC |
31 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Aligos Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fortitude Family Office, LLC | 68 | $505 |